ReviewBioscience reports2015
Diagnostic technologies for circulating tumour cells and exosomes.
Review in Bioscience reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Dynamic changes in liquid biopsy markers during OSCC treatment: A longitudinal study.Bioinformation · 2026Article
- Circulating tumor cells in breast cancer bone metastasis: mechanisms, clinical relevance, and future directions.Cell death discovery · 2025Review
- Innovative Applications of Nanopore Technology in Tumor Screening: An Exosome-Centric Approach.Biosensors · 2025Review
- The multifaceted roles of mucins family in lung cancer: from prognostic biomarkers to promising targets.Frontiers in immunology · 2025Review
- The interplay between the tumor microenvironment and tumor-derived small extracellular vesicles in cancer development and therapeutic response.Cancer biology & therapy · 2024Review
- Five miRNAs identified in fucosylated extracellular vesicles as non-invasive diagnostic signatures for hepatocellular carcinoma.Cell reports. Medicine · 2024Article
- Emerging Microfluidic Tools for Simultaneous Exosomes and Cargo Biosensing in Liquid Biopsy: New Integrated Miniaturized FFF-Assisted Approach for Colon Cancer Diagnosis.Sensors (Basel, Switzerland) · 2023Review
- Review
- Circulating Tumor Cells in Colorectal Cancer: Detection Systems and Clinical Utility.International journal of molecular sciences · 2022Review
- Review
- Nanozyme-Based Lateral Flow Immunoassay (LFIA) for Extracellular Vesicle Detection.Biosensors · 2022Article
- Exosomes as a new frontier of cancer liquid biopsy.Molecular cancer · 2022Review
- Emerging Application of Magnetic Nanoparticles for Diagnosis and Treatment of Cancer.Polymers · 2021Review
- Review
- Small Extracellular Vesicles: Functions and Potential Clinical Applications as Cancer Biomarkers.Life (Basel, Switzerland) · 2021Review
- Stroma-derived extracellular vesicle mRNA signatures inform histological nature of prostate cancer.Journal of extracellular vesicles · 2021Article
- Article
- Extracellular Vesicles as Potential Biomarkers for Early Detection and Diagnosis of Pancreatic Cancer.Biomedicines · 2020Review
- Proteomics analysis of serum small extracellular vesicles for the longitudinal study of a glioblastoma multiforme mouse model.Scientific reports · 2020Article
- The Application of MSCs-Derived Extracellular Vesicles in Bone Disorders: Novel Cell-Free Therapeutic Strategy.Frontiers in cell and developmental biology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Circulating tumour cells (CTCs) and exosomes are promising circulating biomarkers. They exist in easily accessible blood and carry large diversity of molecular information. As such, they can be easily and repeatedly obtained for minimally invasive cancer diagnosis and monitoring. Because of their intrinsic differences in counts, size and molecular contents, CTCs and exosomes pose unique sets of technical challenges for clinical translation-CTCs are rare whereas exosomes are small. Novel technologies are underway to overcome these specific challenges to fully harness the clinical potential of these circulating biomarkers. Herein, we will overview the characteristics of CTCs and exosomes as valuable circulating biomarkers and their associated technical challenges for clinical adaptation. Specifically, we will describe emerging technologies that have been developed to address these technical obstacles and the unique clinical opportunities enabled by technological innovations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.